{"unnormalised": "New Delhi: AIIMS Delhi has announced a clinical trial for a new chemotherapy regimen for Stage 3 lung cancer patients. The trial, registered under CTRI/2024/05/062547, aims to improve survival rates by 15% compared to the standard treatment protocol. Dr. Rajesh Kumar, Head of Oncology at AIIMS, stated that the study will involve 200 patients across India, starting 10/11/2024.", "normalised": "New Delhi: A-I-I-M-S Delhi has announced a clinical trial for a new chemotherapy regimen for Stage three lung cancer patients. The trial, registered under C-T-R-I slash two thousand twenty four slash zero five slash zero six two five four seven, aims to improve survival rates by fifteen percent compared to the standard treatment protocol. Doctor Rajesh Kumar, Head of Oncology at A-I-I-M-S, stated that the study will involve two hundred patients across India, starting tenth november two thousand twenty four."}
{"unnormalised": "The chemotherapy cocktail, tentatively named \"OncoHope,\" combines cisplatin 75mg/m2 with a novel compound developed by the Indian Council of Medical Research (ICMR). Preliminary results from animal studies show a reduction in tumor size by approx. 60% without significant side effects. Patients will be monitored closely for adverse reactions, including nausea, hair loss, and myelosuppression.", "normalised": "The chemotherapy cocktail, tentatively named \"OncoHope,\" combines cisplatin seventy five milligram per meter squared with a novel compound developed by the Indian Council of Medical Research (I-C-M-R). Preliminary results from animal studies show a reduction in tumor size by approximately sixty percent without significant side effects. Patients will be monitored closely for adverse reactions, including nausea, hair loss, and myelosuppression."}
{"unnormalised": "Eligibility criteria include patients aged 18-70 years with histologically confirmed Stage 3 Non-Small Cell Lung Cancer (NSCLC). Participants must have an ECOG performance status of 0 or 1. Those with pre-existing cardiac conditions or other severe comorbidities are excluded. Recruitment will be conducted at AIIMS Delhi, Tata Memorial Centre Mumbai, and Christian Medical College (CMC) Vellore.", "normalised": "Eligibility criteria include patients aged eighteen to seventy years with histologically confirmed Stage three Non-Small Cell Lung Cancer (N-S-C-L-C). Participants must have an E-C-O-G performance status of zero or one. Those with pre-existing cardiac conditions or other severe comorbidities are excluded. Recruitment will be conducted at A-I-I-M-S Delhi, Tata Memorial Centre Mumbai, and Christian Medical College (C-M-C) Vellore."}
{"unnormalised": "Dr. Sharma, a senior oncologist at Tata Memorial, emphasizes the importance of such trials in addressing the growing cancer burden in India. \"With lung cancer being a leading cause of mortality, innovative treatment strategies are crucial. We hope OncoHope will offer a more effective and less toxic option for our patients,\" she said. Further details on the trial can be found on the ICMR website under project code ICMR-ONC-24/LUNG.", "normalised": "Doctor Sharma, a senior oncologist at Tata Memorial, emphasizes the importance of such trials in addressing the growing cancer burden in India. \"With lung cancer being a leading cause of mortality, innovative treatment strategies are crucial. We hope OncoHope will offer a more effective and less toxic option for our patients,\" she said. Further details on the trial can be found on the I-C-M-R website under project code I-C-M-R-O-N-C-twenty four slash L-U-N-G."}
